YER158C Antibody

What is YER158C Antibody and what organism does it target?

YER158C Antibody is a polyclonal antibody raised in rabbits against recombinant Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YER158C protein. This antibody specifically targets the YER158C protein in Baker's yeast and is designed for research applications only, not for diagnostic or therapeutic purposes . The antibody is developed through an antigen affinity purification method and is supplied in liquid form with specific buffer components that maintain stability .

What are the recommended storage conditions for YER158C Antibody?

YER158C Antibody should be stored at -20°C or -80°C upon receipt. It's crucial to avoid repeated freeze-thaw cycles as these can compromise antibody integrity and function . The antibody is supplied in a storage buffer containing 50% glycerol, 0.01M PBS at pH 7.4, and 0.03% Proclin 300 as a preservative . This formulation helps maintain antibody stability during storage. For short-term use, aliquoting the antibody before freezing is recommended to minimize freeze-thaw cycles and preserve antibody functionality.

What applications is YER158C Antibody validated for?

YER158C Antibody has been validated for Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blot (WB) applications that ensure identification of the target antigen . When designing experiments with this antibody, researchers should take into account the specific validation parameters established by the manufacturer. While these are the primarily validated applications, optimization may be required for use in other immunological techniques. Appropriate positive and negative controls should be included when establishing new protocols with this antibody to ensure specificity and sensitivity.

What is the lead time for ordering YER158C Antibody?

The YER158C Antibody is made-to-order with a lead time of 14-16 weeks . This extended production timeline reflects the complex nature of antibody generation and quality control processes. Researchers should plan their experiments accordingly, taking into account this significant lead time. Unlike off-the-shelf antibodies, made-to-order antibodies undergo specific production cycles that ensure quality but require advance planning for experimental timelines.

How can YER158C Antibody be utilized in protein-protein interaction studies?

YER158C Antibody can be employed in co-immunoprecipitation (Co-IP) assays to investigate protein-protein interactions involving the YER158C protein. Though not explicitly validated for Co-IP in the provided information, polyclonal antibodies like YER158C Antibody can often be adapted for this purpose. When setting up such experiments, researchers should optimize antibody concentration, incubation conditions, and washing stringency. A methodological approach would involve:

• Pre-clearing lysates with Protein A/G beads

• Incubating cleared lysates with YER158C Antibody at 4°C overnight

• Adding fresh Protein A/G beads to capture antibody-protein complexes

• Washing thoroughly to remove non-specific binding

• Eluting bound proteins and analyzing by Western blot

This approach requires validation with appropriate controls, including a non-specific rabbit IgG control to assess background binding.

What strategies can be employed to overcome cross-reactivity issues with YER158C Antibody?

Cross-reactivity can present challenges when working with polyclonal antibodies like YER158C Antibody, particularly in complex samples. To address potential cross-reactivity:

• Perform pre-adsorption with related yeast proteins to remove antibodies that might bind non-specifically

• Include blocking steps with 5% milk powder in PBS-T as described in standard ELISA protocols

• Implement more stringent washing conditions (increased detergent concentration or additional washes)

• Consider column purification to isolate the specific fraction of antibodies targeting the desired epitope

• Validate specificity using YER158C knockout strains as negative controls

These approaches must be empirically tested for each experimental system, as cross-reactivity patterns may vary between different sample types and experimental conditions.

How can YER158C Antibody be applied in studies of yeast protein localization?

YER158C Antibody can be adapted for immunofluorescence microscopy to determine subcellular localization of the target protein. While not explicitly listed among validated applications , immunofluorescence is a logical extension for polyclonal antibodies with confirmed specificity. A methodological approach would include:

• Fixation of yeast cells using formaldehyde or methanol-based protocols

• Spheroplasting and permeabilization to allow antibody access

• Blocking with appropriate agents (BSA or normal serum)

• Primary incubation with YER158C Antibody at optimized dilutions

• Secondary detection using fluorophore-conjugated anti-rabbit IgG

• Counterstaining of cellular structures (nucleus, cell wall) for reference

• Confocal microscopy analysis with appropriate controls

Optimization of fixation conditions, antibody concentration, and incubation times will be critical for successful localization studies.

What are the optimal dilution ranges for YER158C Antibody in different applications?

While specific dilution recommendations weren't provided in the search results for YER158C Antibody, general principles for antibody dilution optimization can be applied:

For ELISA applications:

• Begin with a starting concentration of 10 μg/mL with serial 1:5 dilutions as described in standard protocols

• Perform a checkerboard titration to determine optimal antibody concentration that maximizes signal-to-noise ratio

• Include both positive and negative controls at each dilution point

• Calculate area under the curve (AUC) using appropriate software (e.g., GraphPad Prism) to quantitatively assess binding profiles

For Western Blot applications:

• Start with dilutions in the range of 1:500 to 1:2000

• Optimize blocking conditions using 5% milk powder in PBS-T as outlined in standard protocols

• Evaluate signal intensity and background at different dilutions

• Consider extended incubation times (overnight at 4°C) for more dilute antibody solutions

For each application, optimization should be performed systematically and results documented for reproducibility.

How should researchers troubleshoot inconsistent results when using YER158C Antibody in ELISA?

When encountering inconsistent ELISA results with YER158C Antibody, implement the following troubleshooting strategy:

• Evaluate antibody integrity by testing freshly thawed aliquots versus previously used antibody

• Assess plate coating conditions including concentration of capture antigen and incubation parameters

• Modify blocking agents and duration (standard protocols suggest 1-hour blocking with 5% milk powder in PBS-T)

• Adjust washing stringency (number of washes, volume, and detergent concentration)

• Vary secondary antibody dilutions to optimize detection sensitivity

• Consider alternative detection systems if signal variability persists

• Run multiple replicates (standard protocols suggest at least three replicates for each condition)

Notably, if ELISA replicates remain inconsistent over more than three experiments, consider excluding the antibody from further analysis, as suggested by standard practices in antibody characterization .

What controls should be included when using YER158C Antibody in Western blotting experiments?

Comprehensive controls are essential for reliable Western blotting with YER158C Antibody:

Positive controls:

• Purified recombinant YER158C protein at known concentrations

• Lysates from wild-type S. cerevisiae strains expressing the target protein

• Gradient loading of positive samples to establish detection sensitivity

Negative controls:

• Lysates from YER158C knockout yeast strains

• Non-yeast samples that should not contain cross-reactive proteins

• Primary antibody omission control to assess secondary antibody specificity

Procedural controls:

• Loading control antibodies targeting constitutively expressed yeast proteins

• Pre-stained molecular weight markers to verify transfer efficiency

• Ponceau S staining to confirm protein transfer

These controls should be consistently included across experiments to ensure reproducibility and facilitate troubleshooting if unexpected results occur.

How should researchers quantify YER158C Antibody binding in ELISA assays?

For quantitative analysis of YER158C Antibody binding in ELISA assays, implement the following methodological approach:

• Generate standard curves using purified recombinant YER158C protein at known concentrations

• Measure optical density at 450 nm after TMB substrate development and sulfuric acid stopping reaction

• Calculate area under the curve (AUC) using appropriate software such as GraphPad Prism version 8.0.0 or equivalent

• Represent data as mean ± standard error of the mean (SEM) from at least three independent experiments

• Establish a cutoff value for positive binding based on negative control readings (typically 2-3 standard deviations above mean negative control)

• Implement four-parameter logistic regression for more accurate quantification of antibody-antigen interactions

This quantitative approach enables objective comparison between experimental conditions and statistical validation of results.

What are potential pitfalls in interpreting YER158C Antibody binding specificity?

When interpreting YER158C Antibody binding specificity, researchers should be aware of several potential pitfalls:

• Cross-reactivity with structurally similar yeast proteins may produce false-positive signals

• Post-translational modifications of the target protein may affect epitope accessibility and antibody recognition

• Non-specific binding to the solid phase (in ELISA) or membrane (in Western blot) can create background signal

• Matrix effects from complex biological samples may interfere with binding

• Lot-to-lot variations in polyclonal antibody preparations can impact reproducibility

• Denaturation conditions in Western blotting may expose or mask epitopes compared to native conditions in ELISA

To address these pitfalls, incorporate multiple complementary techniques for validation, include appropriate controls, and consider epitope mapping studies to better characterize antibody binding properties.

How can researchers determine if YER158C Antibody is suitable for detecting protein-protein interactions?

To evaluate YER158C Antibody suitability for protein-protein interaction studies, researchers should follow this systematic approach:

• First assess if the antibody epitope overlaps with potential protein interaction domains by analyzing protein sequence data

• Perform preliminary co-immunoprecipitation experiments with controls to determine if the antibody:
  a. Efficiently captures the target protein under native conditions
  b. Does not disrupt known protein-protein interactions
  c. Provides sufficient yield of complexes for downstream analysis

• Consider comparative analysis with other antibodies targeting different epitopes of the same protein

• Validate observed interactions using reciprocal co-immunoprecipitation with antibodies against interaction partners

• Complement antibody-based approaches with orthogonal methods such as proximity ligation assays or FRET-based techniques

This multi-faceted evaluation will determine whether the antibody can reliably detect physiologically relevant protein-protein interactions without introducing artifacts.

How can YER158C Antibody be adapted for high-throughput screening applications?

Adapting YER158C Antibody for high-throughput screening requires systematic optimization and standardization:

• Implement automated liquid handling for consistent antibody dispensing across multiple plates

• Miniaturize assay formats from standard 96-well to 384-well plates while maintaining signal-to-noise ratios

• Optimize antibody concentration to balance sensitivity and cost-effectiveness

• Develop robust positive and negative controls for each plate to normalize inter-plate variability

• Consider using real-time cell analysis (RTCA) approaches with the xCelligence RTCA HT Analyzer for kinetic assessment of antibody binding effects

• Implement automated image acquisition and analysis for cell-based screens

• Validate high-throughput protocols against established standard assays to ensure comparability

This adaptation requires extensive validation to ensure that sensitivity and specificity are maintained despite reduced volumes and increased throughput.

What approaches can be used to determine the epitope specificity of YER158C Antibody?

Determining epitope specificity of YER158C Antibody requires a multi-method approach:

• Peptide array analysis:

  • Synthesize overlapping peptides covering the entire YER158C sequence

  • Screen the antibody against these peptides to identify binding regions

  • Refine with alanine scanning of positive peptides to identify critical residues

• Hydrogen-deuterium exchange mass spectrometry (HDX-MS):

  • Compare deuterium uptake patterns of YER158C protein alone versus antibody-bound

  • Regions with reduced deuterium exchange when antibody is bound indicate epitope locations

• X-ray crystallography or cryo-EM analysis:

  • Attempt to crystallize the antibody-antigen complex

  • Determine atomic resolution structure to precisely map the epitope

• Competitive binding assays:

  • Design experiments where the antibody competes with known ligands or other antibodies

  • Blocked binding suggests overlapping epitopes

These complementary approaches provide a comprehensive understanding of the structural basis for antibody specificity.

How can computational approaches enhance experimental design with YER158C Antibody?

Computational approaches can significantly enhance experimental design with YER158C Antibody:

• Structural bioinformatics and molecular simulations can predict antibody-antigen interactions, similar to approaches used in the GUIDE program for antibody optimization

• Machine learning algorithms can analyze binding patterns across multiple experiments to identify optimal conditions

• Molecular dynamics simulations can predict how buffer conditions might affect epitope accessibility

• In silico epitope prediction tools can identify potentially immunogenic regions of YER158C protein

• Computational design of mutant variants can help test binding specificity hypotheses

• Supercomputing resources, similar to those used in antibody redesign projects , can simulate large-scale molecular interactions to predict cross-reactivity

As demonstrated in related antibody research, computational binding predictions driven by advanced structural bioinformatics and molecular simulations allow for optimization across multiple parameters simultaneously .

How does YER158C Antibody performance compare to alternative detection methods for the target protein?

When comparing YER158C Antibody performance against alternative detection methods, consider the following methodological assessment:

• Mass spectrometry-based approaches:

  • Provide higher specificity through peptide mass fingerprinting

  • Enable absolute quantification when using isotope-labeled standards

  • May detect post-translational modifications missed by antibody-based methods

  • Typically require more sophisticated equipment and expertise

• Genetic tagging approaches (GFP, FLAG, etc.):

  • Offer high specificity through defined epitope tags

  • Enable live-cell imaging when using fluorescent tags

  • May alter protein function or localization

  • Require genetic modification of the host organism

• Aptamer-based detection:

  • Potentially offers similar specificity with different binding characteristics

  • May provide advantages in certain buffer conditions where antibodies perform poorly

  • Typically less established for yeast proteins

Comparative validation should include side-by-side testing with standardized samples, assessing detection limits, dynamic range, and reproducibility for each method.

What factors should researchers consider when comparing results from different lots of YER158C Antibody?

When comparing results from different antibody lots, researchers should systematically address the following factors:

• Lot-specific validation:

  • Perform side-by-side testing of basic binding parameters

  • Document lot-specific optimal dilutions for each application

  • Create standard curves with purified antigen to normalize between lots

• Documentation and standardization:

  • Maintain detailed records of lot numbers used in experiments

  • Standardize critical reagents and protocols across experiments

  • Consider purchasing larger lots for long-term projects to minimize variability

• Statistical analysis:

  • Implement appropriate statistical methods to determine if lot differences are significant

  • Consider multilevel models that account for lot as a random effect

  • Calculate and report confidence intervals rather than just p-values

• Experimental design:

  • Include internal controls that can be used to normalize between lots

  • Consider replicate designs that incorporate multiple lots to assess variability

  • When possible, repeat critical experiments with different lots to ensure reproducibility

Adhering to these systematic approaches helps distinguish biological findings from technical variability introduced by antibody lot differences.

What strategies can resolve weak or absent signals when using YER158C Antibody in Western blotting?

When encountering weak or absent Western blot signals with YER158C Antibody, implement this systematic troubleshooting approach:

• Sample preparation optimization:

  • Ensure complete protein extraction from yeast cells using appropriate lysis buffers

  • Incorporate protease inhibitors to prevent target degradation

  • Optimize protein loading quantity (typically 20-50 μg total protein)

• Transfer efficiency improvement:

  • Adjust transfer conditions for high molecular weight proteins (lower current, longer time)

  • Consider using PVDF membrane instead of nitrocellulose for stronger protein binding

  • Verify transfer using reversible staining methods (Ponceau S)

• Antibody binding enhancement:

  • Increase primary antibody concentration or incubation time (overnight at 4°C)

  • Optimize blocking conditions to reduce background while preserving specific binding

  • Consider alternative blocking agents (BSA instead of milk for phospho-specific epitopes)

• Detection sensitivity improvement:

  • Implement more sensitive detection systems (enhanced chemiluminescence)

  • Consider amplification steps such as biotin-streptavidin systems

  • Optimize exposure times for digital imaging systems

These methodological adjustments should be implemented sequentially while maintaining appropriate controls to identify the specific limiting factor.

How can researchers address non-specific binding when using YER158C Antibody?

To address non-specific binding issues with YER158C Antibody, implement this comprehensive strategy:

• Blocking optimization:

  • Test different blocking agents (5% milk powder in PBS-T as used in standard protocols , BSA, normal serum)

  • Extend blocking time beyond the standard one hour if background persists

  • Consider adding low concentrations of detergents or carrier proteins to antibody diluents

• Washing protocol enhancement:

  • Increase wash buffer stringency (higher detergent concentration)

  • Extend washing times and increase the number of washes

  • Implement temperature variations (room temperature vs. 4°C) to optimize specificity

• Antibody dilution refinement:

  • Perform careful titration experiments to identify optimal concentrations

  • Consider pre-adsorption against related proteins to remove cross-reactive antibodies

  • Implement stringent negative controls to establish background thresholds

• Sample preparation refinement:

  • Include additional purification steps to remove components that may cause non-specific binding

  • Pre-clear samples with protein A/G beads to remove endogenous immunoglobulins

  • Adjust salt concentration in buffers to reduce ionic interactions

Systematic implementation and documentation of these approaches will help identify the optimal conditions for specific detection while minimizing background.

How might YER158C Antibody be utilized in emerging single-cell analysis techniques?

YER158C Antibody could be adapted for cutting-edge single-cell analysis through several innovative approaches:

• Mass cytometry (CyTOF) integration:

  • Conjugate YER158C Antibody with rare earth metals for mass cytometry detection

  • Develop multiplexed panels including YER158C alongside other yeast proteins

  • Enable quantitative analysis of protein expression at single-cell resolution

• Single-cell Western blotting:

  • Adapt YER158C Antibody protocols for microfluidic single-cell Western blot platforms

  • Optimize detection sensitivity for the lower protein amounts present in individual cells

  • Correlate YER158C expression with other cellular parameters

• In situ protein analysis:

  • Develop proximity ligation assays using YER158C Antibody to detect protein interactions in fixed yeast cells

  • Implement highly multiplexed immunofluorescence using cyclic immunostaining or DNA-barcoded antibodies

  • Correlate protein localization with functional cellular parameters

These emerging applications require thorough validation and optimization but offer unprecedented insights into cell-to-cell variability in YER158C expression and function.

What considerations are important when developing anti-idiotypic antibodies against YER158C Antibody?

Developing anti-idiotypic antibodies against YER158C Antibody requires careful consideration of several factors:

• Selection strategy design:

  • Perform selection of anti-idiotypic antibodies in the presence of isotype sub-class matched antibodies as blockers to ensure idiotope specificity

  • Include human serum during selection to avoid matrix effects in the final assay

  • Guide the selection method to generate specific types of anti-idiotypic antibodies with different binding modes

• Binding mode characterization:

  • Differentiate between inhibitory antibodies (Type 1) that block antigen binding site versus non-inhibitory antibodies (Type 2) that bind outside the antigen binding site

  • Consider developing complex-specific binders (Type 3) for specialized applications

  • Validate binding modes through competitive binding assays

• Production and purification:

  • Consider recombinant antibody production methods like phage display with HuCAL technology for greater consistency

  • Implement affinity maturation to optimize binding characteristics

  • Develop purification strategies that maintain idiotype recognition

• Validation and application:

  • Establish specificity through extensive cross-reactivity testing

  • Validate utility in immunoassay development

  • Assess stability and reproducibility across production lots

These considerations follow established principles for anti-idiotypic antibody development while addressing the specific characteristics of YER158C Antibody .

What are the most critical factors for successful implementation of YER158C Antibody in research protocols?

The most critical factors for successful implementation of YER158C Antibody in research protocols include:

• Stringent quality control and validation:

  • Verify antibody specificity through multiple complementary techniques

  • Establish optimal working dilutions for each application

  • Document lot-to-lot consistency through standardized testing

• Appropriate experimental design:

  • Include comprehensive positive and negative controls

  • Implement biological and technical replicates (minimum three independent experiments)

  • Design experiments that account for potential cross-reactivity with related yeast proteins

• Optimized sample preparation:

  • Develop protocols that preserve YER158C protein integrity

  • Address potential interfering substances in complex biological samples

  • Standardize sample collection and processing to minimize variability

• Rigorous data analysis:

  • Implement appropriate statistical methods for quantitative analyses

  • Establish clear criteria for positive versus negative results

  • Consider multiple analytical approaches to confirm findings

• Transparent reporting:

  • Document detailed methodological parameters including antibody dilutions, incubation times, and buffer compositions

  • Report both positive and negative findings to advance the field

  • Share optimized protocols to enhance reproducibility across laboratories